Biogen Ramping Up For Antegren Launch; Relapsed MS Patients One Target
Executive Summary
Biogen Idec expects to position Antegren to multiple sclerosis patients who are experiencing breakthrough disease upon approval of the monoclonal antibody
You may also be interested in...
Biogen Idec/Elan Tysabri Clears FDA; Promotion Will Focus On Monotherapy
Biogen Idec and Elan plan to promote the once-monthly multiple sclerosis therapy Tysabri primarily as first-line monotherapy to patients who have discontinued previous therapy
Biogen Idec/Elan Tysabri Clears FDA; Promotion Will Focus On Monotherapy
Biogen Idec and Elan plan to promote the once-monthly multiple sclerosis therapy Tysabri primarily as first-line monotherapy to patients who have discontinued previous therapy
Biogen Idec Addressing Avonex Liquid Formulation Manufacturing Problems
Biogen Idec is working to address Avonex fill-finish manufacturing problems with the recently approved liquid formulation of the multiple sclerosis therapy